CN114222737B - NF-κB诱导激酶的小分子抑制剂 - Google Patents

NF-κB诱导激酶的小分子抑制剂 Download PDF

Info

Publication number
CN114222737B
CN114222737B CN202080057418.XA CN202080057418A CN114222737B CN 114222737 B CN114222737 B CN 114222737B CN 202080057418 A CN202080057418 A CN 202080057418A CN 114222737 B CN114222737 B CN 114222737B
Authority
CN
China
Prior art keywords
phenyl
ethynyl
pyrimidin
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080057418.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114222737A (zh
Inventor
J·K·巴贝
柴文英
W·埃克莱斯
M·D·哈克
A·T·赫尔曼
W·M·琼斯
P·J·克劳丘克
K·D·克鲁特
A·D·勒贝克
D·J·皮佩尔
A·R·罗维拉
R·L·沃林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202410972792.2A priority Critical patent/CN118908957A/zh
Publication of CN114222737A publication Critical patent/CN114222737A/zh
Application granted granted Critical
Publication of CN114222737B publication Critical patent/CN114222737B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080057418.XA 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂 Active CN114222737B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410972792.2A CN118908957A (zh) 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US62/855144 2019-05-31
US201962907833P 2019-09-30 2019-09-30
US62/907833 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410972792.2A Division CN118908957A (zh) 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂

Publications (2)

Publication Number Publication Date
CN114222737A CN114222737A (zh) 2022-03-22
CN114222737B true CN114222737B (zh) 2024-07-26

Family

ID=71108552

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080057418.XA Active CN114222737B (zh) 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂
CN202410972792.2A Pending CN118908957A (zh) 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410972792.2A Pending CN118908957A (zh) 2019-05-31 2020-05-29 NF-κB诱导激酶的小分子抑制剂

Country Status (37)

Country Link
US (3) US11254673B2 (https=)
EP (2) EP3976597B1 (https=)
JP (2) JP7547387B2 (https=)
KR (1) KR20220027871A (https=)
CN (2) CN114222737B (https=)
AU (1) AU2020282005B2 (https=)
BR (1) BR112021023796A2 (https=)
CL (1) CL2021003142A1 (https=)
CO (1) CO2021017838A2 (https=)
CR (1) CR20210587A (https=)
DK (1) DK3976597T3 (https=)
DO (1) DOP2021000244A (https=)
EC (1) ECSP21093623A (https=)
ES (1) ES2989387T3 (https=)
FI (1) FI3976597T3 (https=)
HR (1) HRP20241352T1 (https=)
HU (1) HUE068694T2 (https=)
IL (1) IL288387B2 (https=)
JO (1) JOP20210318B1 (https=)
LT (1) LT3976597T (https=)
MA (1) MA56038B1 (https=)
MD (1) MD3976597T2 (https=)
MX (1) MX2021014679A (https=)
MY (1) MY205653A (https=)
PE (1) PE20220768A1 (https=)
PH (1) PH12021553011A1 (https=)
PL (1) PL3976597T3 (https=)
PT (1) PT3976597T (https=)
RS (1) RS66105B1 (https=)
SA (1) SA521430960B1 (https=)
SG (1) SG11202112994WA (https=)
SI (1) SI3976597T1 (https=)
SM (1) SMT202400418T1 (https=)
TW (2) TWI850390B (https=)
UA (1) UA130430C2 (https=)
UY (1) UY38721A (https=)
WO (1) WO2020239999A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114222737B (zh) * 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
IL316886A (en) * 2022-05-11 2025-01-01 Janssen Pharmaceutica Nv History of pyrrolidinones as NF kappa B kinase inhibitors
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
EP4637773A1 (en) 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
IL326016A (en) 2023-07-28 2026-03-01 Boehringer Ingelheim Int Process for manufacturing a HER2 inhibitor
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
JP2026022634A (ja) * 2024-07-30 2026-02-12 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810110A (zh) * 2017-11-22 2019-05-28 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
JP2008509138A (ja) * 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MX2013010513A (es) * 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
JP2015507001A (ja) 2012-02-17 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式化合物及びその使用方法
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
US20150057260A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Alkynyl alcohols and methods of use
US20160096850A9 (en) * 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
AU2015334917B2 (en) 2014-10-23 2019-08-29 Janssen Pharmaceutica Nv New compounds as NIK inhibitors
BR112017008039B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
JP6616412B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
JP2018510140A (ja) 2015-02-25 2018-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
WO2018037059A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN110831940B (zh) 2017-07-06 2023-06-20 詹森药业有限公司 作为nik抑制剂的新取代的氮杂吲哚啉衍生物
CN114222737B (zh) * 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810110A (zh) * 2017-11-22 2019-05-28 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo;Zhiqiang Li等;《J. Med. Chem.》;20200327;第63卷;第4390页表1、第4392页表2、表3、第4393页表4 *

Also Published As

Publication number Publication date
US20230080834A1 (en) 2023-03-16
WO2020239999A1 (en) 2020-12-03
ES2989387T3 (es) 2024-11-26
EP4467199A3 (en) 2025-03-05
US20210300918A1 (en) 2021-09-30
SMT202400418T1 (it) 2024-11-15
IL288387B1 (en) 2025-09-01
UY38721A (es) 2020-11-30
FI3976597T3 (fi) 2024-09-25
BR112021023796A2 (pt) 2022-02-08
TW202110842A (zh) 2021-03-16
MD3976597T2 (ro) 2025-01-31
MY205653A (en) 2024-11-02
KR20220027871A (ko) 2022-03-08
LT3976597T (lt) 2024-10-10
PE20220768A1 (es) 2022-05-16
US20240199605A1 (en) 2024-06-20
RS66105B1 (sr) 2024-11-29
JP7547387B2 (ja) 2024-09-09
JP2024167319A (ja) 2024-12-03
SG11202112994WA (en) 2021-12-30
IL288387A (en) 2022-01-01
TWI906955B (zh) 2025-12-01
MA56038B1 (fr) 2024-11-29
TW202517638A (zh) 2025-05-01
EP3976597B1 (en) 2024-08-28
CN118908957A (zh) 2024-11-08
TWI850390B (zh) 2024-08-01
UA130430C2 (uk) 2026-02-18
SI3976597T1 (sl) 2024-11-29
JOP20210318B1 (ar) 2025-10-01
EP3976597A1 (en) 2022-04-06
HRP20241352T1 (hr) 2024-12-20
CR20210587A (es) 2022-02-11
US11827634B2 (en) 2023-11-28
SA521430960B1 (ar) 2024-11-12
PH12021553011A1 (en) 2022-11-07
DK3976597T3 (da) 2024-09-09
ECSP21093623A (es) 2022-01-31
PT3976597T (pt) 2024-10-22
HUE068694T2 (hu) 2025-01-28
MA56038A (fr) 2022-04-06
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
PL3976597T3 (pl) 2024-12-16
JOP20210318A1 (ar) 2023-01-30
CO2021017838A2 (es) 2022-01-17
CL2021003142A1 (es) 2022-08-19
IL288387B2 (en) 2026-01-01
AU2020282005B2 (en) 2026-02-12
MX2021014679A (es) 2022-04-06
CA3143350A1 (en) 2020-12-03
US11254673B2 (en) 2022-02-22
JP2022534302A (ja) 2022-07-28
EP4467199A2 (en) 2024-11-27
DOP2021000244A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
CN114222737B (zh) NF-κB诱导激酶的小分子抑制剂
JP6770127B2 (ja) Ｂｔｋ阻害薬としての一級カルボキサミド類
TWI457339B (zh) 稠合雜芳香環吡咯啶酮
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
JP2021506979A (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール−ビピリジンアミン誘導体
KR20160056896A (ko) Ｐｉｍ 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물
WO2014121055A2 (en) Flap modulators
TW201429959A (zh) 雜環核荷爾蒙受體調節劑
CA3143350C (en) Small molecule inhibitors of nf-kb inducing kinase
CN118525018A (zh) 一种联炔类化合物及其应用
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
CN119546602A (zh) 作为NFκB诱导激酶的抑制剂的吡咯烷酮衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant